With Assistance from U.S. State Department's 'Bio-Industry Initiative' (BII) Program, Grant Life Sciences In-Licenses Proprietary Technology from Two Russian Scientists That Detects Presence of Cervical Cancer-Causing HPV Types

LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today the signing of a final agreement with Dr. Peter Sveshnikov and Dr. Vsevolod Kiselev of the Russian Federation, for the in-licensing of certain of their technologies that are highly complementary to Grants' antibody-based test for detecting cervical cancer. The intellectual property (IP) associated with the Sveshnikov/Kiselev technology has been developed as a result of funding from the U.S. State Department’s Bio-Industry Initiative (BII) program. The BII is designed to foster medical and other biological research and development in the former Soviet Union by converting former biowarfare scientists to productive peacetime activities.